All In Biotech

Drug Trial Radar · NCT01820520

Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery

Last checked: Nov 20, 2026Latest source record: May 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

22

Actual

Start

Jan 2013

Primary completion

Feb 2014

Study completion Feb 2014

Sponsor

Lead sponsor
Asociación para Evitar la Ceguera en MéxicoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 28, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study designed to evaluate the safety and efficacy of double staining with brilliant blue G 0.025% as an adjuvant to macular surgery. Patients undergoing surgery for macular hole or epiretinal membrane will be included. Safety will be evaluated by optic coherence tomography, pattern reversal electroretinogram and multifocal electroretinogram.

Conditions

  • Macular Hole
  • Epiretinal Membrane

Interventions

  • brilliant blue GDrug

    Double staining with brilliant blue G 0.025% for macular surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Thickness of ganglion cell layer - inner plexiform layer measured by optical coherence tomographyTime frame: 6 months
  2. Amplitude of pattern reversal electroretinogramTime frame: 6 months
  3. Amplitude of b-wave of multifocal electroretinogramTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asociación para Evitar la Ceguera en México

    Mexico City, Mexico City, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.